Form 8-K - Current report:
SEC Accession No. 0001213900-25-016278
Filing Date
2025-02-24
Accepted
2025-02-24 07:10:13
Documents
14
Period of Report
2025-02-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0231907-8k_nektar.htm   iXBRL 8-K 25225
2 PRESS RELEASE TITLED "NEKTAR ANNOUNCES CLINICAL TRIAL AGREEMENT TO EVALUATE REZP ea023190701ex99-1_nektar.htm EX-99.1 29152
  Complete submission text file 0001213900-25-016278.txt   233386

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nktr-20250224.xsd EX-101.SCH 3009
4 XBRL LABEL FILE nktr-20250224_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE nktr-20250224_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0231907-8k_nektar_htm.xml XML 3565
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 25654178
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)